Dr. Ogilvie has been influential in setting and directing health policy on reproductive health, sexually transmitted infections, HPV screening and the HPV vaccine, both in Canada and globally. She provides advice and consultation to national and international institutions, including the Canadian Partnership Against Cancer, Public Health Agency of Canada, the World Health Organization (WHO), and Ministries of Health on STI, HIV and HPV vaccine policy and programming.
‘I’m truly delighted that our team was able to secure this highly competitive funding. It’s a tremendous honour, and an indication of the exceptional innovative and relevant research that is going on at BC Women’s and PHSA agencies. It’s a wonderful acknowledgement that here in BC, we are indeed leaders in the global effort to eliminate cervical cancer.’
As principal investigator, her research has attracted over $13 million in grants, receiving funding from PHAC, CIHR, Michael Smith Foundation for Health Research (MSFHR), and private foundations, among others. Dr. Ogilvie has published over 100 peer-reviewed manuscripts and speaks widely at international and national research and education conferences.